← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	879	+3	+0.3%	$19.4B
2	2 Charles River Laboratories CRL $14.4B	286	+22	+8%	$3.8B
3	3 DELISTED CATALENT, INC. CTLT	186	+12	+7%	$2.93B
4	ISEE 4 DELISTED IVERIC bio, Inc. Common Stock ISEE	182	+20	+12%	$1.71B
5	5 DELISTED bluebird bio BLUE	177	-10	-5%	$1.9B
6	6 Precigen PGEN $2.64B	169	-22	-12%	$2.45B
7	7 Ultragenyx Pharmaceutical RARE $1.47B	162	0	0%	$1.81B
8	8 Sarepta Therapeutics SRPT $1.78B	148	+16	+12%	$661M
9	9 DELISTED SANGAMO THERAPEUTICS INC SGMO	136	-7	-5%	$268M
10	10 PTC Therapeutics PTCT $4.98B	118	-1	-0.8%	$202M
11	AGTC 11 DELISTED Applied Genetic Technologies Corporation AGTC	94	+4	+4%	$153M
12	SIOX 12 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	81	+11	+16%	$323M
13	ATHX 13 DELISTED Athersys, Inc. Common Stock ATHX	78	+14	+22%	$32.8M
14	14 DELISTED Adverum Biotechnologies ADVM	77	-5	-6%	$49.8M
15	15 Atara Biotherapeutics ATRA $96M	74	+3	+4%	$493M
16	16 Lineage Cell Therapeutics LCTX $232M	74	+8	+12%	$99.9M
17	17 Regenxbio RGNX $454M	69	+5	+8%	$147M
18	BLCM 18 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	67	-11	-14%	$229M
19	19 Rocket Pharmaceuticals RCKT $243M	66	+8	+14%	$147M
20	20 Intellia Therapeutics NTLA $1.6B	62	+62	–	$302M
21	21 uniQure QURE $1.45B	59	+2	+4%	$60M
22	22 Fortress Biotech FBIO $63.4M	52	+8	+18%	$21.8M
23	23 Vericel Corp VCEL $2.06B	52	+3	+6%	$24.5M
24	24 Voyager Therapeutics VYGR $124M	48	+5	+12%	$116M
25	ADAP 25 DELISTED Adaptimmune Therapeutics ADAP	47	-2	-4%	$260M